Journal article

The Relationship between Sleep Quality and Brain Amyloid Burden

Belinda M Brown, Stephanie R Rainey-Smith, Victor L Villemagne, Michael Weinborn, Romola S Bucks, Hamid R Sohrabi, Simon M Laws, Kevin Taddei, S Lance Macaulay, David Ames, Christopher Fowler, Paul Maruff, Colin L Masters, Christopher C Rowe, Ralph N Martins

SLEEP | OXFORD UNIV PRESS INC | Published : 2016


STUDY OBJECTIVES: To evaluate the association between self-reported sleep quality and levels of brain β-amyloid (Aβ) burden, and to determine the effect of the apolipoprotein E (APOE) ε4 allele on any associations found. METHODS: This study is a cross-sectional analysis of 184 cognitively healthy men and women aged over 60 y. We measured sleep quality factors: specifically, sleep duration, latency (time taken to fall asleep), disturbances, efficiency, daytime dysfunction, and overall sleep quality, using the Pittsburgh Sleep Quality Index. All participants underwent Aβ positron emission tomography imaging for the quantification of brain Aβ burden and were APOE genotyped. Linear regression an..

View full abstract


Funding Acknowledgements

This was not an industry supported study. Funding for the AIBL study is provided by the CSIRO Flagship Collaboration Fund and the Science and Industry Endowment Fund (SIEF) in partnership with Edith Cowan University (ECU), The Florey Institute of Neuroscience and Mental Health, Alzheimer's Australia (AA), National Ageing Research Institute (NARI), Austin Health, CogState Ltd., Hollywood Private Hospital, and Sir Charles Gairdner Hospital. The study also receives funding from the National Health and Medical Research Council (NHMRC), the Dementia Collaborative Research Centres program (DCRC2) and the McCusker Alzheimer's Research Foundation, and Operational Infrastructure Support from the Government of Victoria. Dr. Villemagne has financial interests in GE Healthcare, Piramal Imaging, and Novartis, Dr. Bucks has financial interests in NHMRC, Hogrefe Publisher, Speechmark Publisher, Parkinson's Western Australia: Zrinski Grant and Brain Foundation. Dr. Sohrabi has financial interests in Takeda Pharmaceutical Company and Pfizer Inc. Dr. Macaulay has financial interests in CSIRO and various small holdings. Dr. Ames has financial interests in PranaBio and Eli Lilly. Dr. Masters has financial interests in PranaBio, Eli Lilly, and Actinogen. Dr. Martins has financial interests in Alzhyme. Drs. Brown, Rainey-Smith, Weinborn, Laws, Taddei, Fowler, Maruff, and Rowe have indicated no financial conflicts of interest. The work was performed at the School of Medical Sciences, Edith Cowan University, Joondalup, Western Australia; Sir James McCusker Alzheimer's Disease Research Unit, Hollywood Private Hospital, Nedlands, Western Australia; Austin Health, Department of Nuclear Medicine and Centre for PET, Heidelberg, Victoria, Australia; and the Florey Institute for Neurosciences and Mental Health, University of Melbourne, Victoria, Australia.